2023-503658-11-00招募中3 期
J1I-MC-GZBK: A Master Protocol to Investigate the Efficacy and Safety of LY3437943 Once Weekly in Participants with Type 2 Diabetes Mellitus Who Have Obesity or Overweight: A Randomized Double-Blind, Placebo-Controlled Trial (TRIUMPH-2)
适应症
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 入组人数
- 235
- 试验地点
- 14
- 主要终点
- Percent Change from Baseline in Body Weight
研究概览
简要总结
The purpose of this study is to evaluate the efficacy and safety of retatrutide in participants with type 2 diabetes who have obesity or overweight (J1I-MC-GZBK master protocol)
入排标准
- 年龄范围
- 18 years 至 65+ years（65+ Years, 18-64 Years）
- 接受健康志愿者
- 是
入选标准
- •Be Overweight or Have Obesity
- •Have Type 2 Diabetes
- •Are on stable treatment for Type 2 Diabetes for at least 90 days before starting study.
- •History of unsuccessful weight loss.
排除标准
- •Have a self-reported or documented change in body weight >5 kg within 90 days before screening.
- •Have a prior or planned surgical treatment for obesity.
- •Have Type 1 diabetes
- •Have had 1 episode of severe hypoglycemia or hypoglycemia unawareness ≤6 months before screening.
- •Have acute or chronic hepatitis
结局指标
主要结局
Percent Change from Baseline in Body Weight
Percent Change from Baseline in Body Weight
次要结局
未报告次要终点
研究者
Lilly Clinical Trials information desk
Scientific
Eli Lilly & Co.
研究点 (14)
Loading locations...
相似试验
招募中
3 期
A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease (TRIUMPH-3)ObesityCardiovascular Disease2023-503659-88-00Eli Lilly & Co.389
招募中
3 期
177Lu-edotreotide compared to everolimus in neuroendocrine tumors of the lung and thymus2022-502154-13-00Grupo Espanol De Tumores Neuroendocrinos135
招募中
3 期
A Study of LY3437943 in Participants Who Have Obesity or Overweight (TRIUMPH-1)Osteoarthritis, KneeObesity2023-503657-35-00Eli Lilly & Co.440
招募中
3 期
52 weeks double-blind, double-dummy, randomized placebo-controlled trial to evaluate safety, efficacy and tolerability of remibrutinib in comparison to placebo with omalizumab as active control in adult patients with CSU and inadequate response to H1-antihistamine and an open-label 52-week optional extension to assess long-term efficacy, safety and tolerability of remibrutinib 25 mg b.i.d.2022-502161-19-00Novartis Pharma AG214
招募中
2 期
Administration of Gilteritinib to eliminate MRD in patients with AML and FLT3-ITD mutation.2025-521875-30-00Hellenic Society Of Hematology58